Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
3
75%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated2
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

completed125%
terminated250%
withdrawn125%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects

NCT01165450
completedphase_2

A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)

NCT00820196
terminatedphase_1

The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers

NCT00820703
withdrawnphase_2

A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects

NCT00821561

Clinical Trials (4)

Showing 4 of 4 trials
NCT01165450Phase 2

Efficacy and Safety Study of Nexagon for Persistent Corneal Epithelial Defects

Terminated
NCT00820196Phase 2

A Trial to Assess the Safety and Activity of Nexagon® for the Treatment of Venous Leg Ulcers (The NOVEL Study)

Completed
NCT00820703Phase 1

The ASCEND Study: A Study to Investigate the Safety and Clinical Effect of Nexagon to Treat Slow Healing Diabetic Foot Ulcers

Terminated
NCT00821561Phase 2

A Study to Investigate the Safety and Clinical Effect of Nexagon® to Treat Persistent Epithelial Defects

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4